Eupraxia Pharmaceuticals Inc. (TSX: EPRX)

Canada flag Canada · Delayed Price · Currency is CAD
5.03
+0.43 (9.35%)
Nov 20, 2024, 3:59 PM EST
-21.41%
Market Cap 179.18M
Revenue (ttm) n/a
Net Income (ttm) -38.12M
Shares Out 35.62M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 144,371
Open 4.75
Previous Close 4.60
Day's Range 4.74 - 5.45
52-Week Range 3.07 - 7.64
Beta 1.23
Analysts n/a
Price Target n/a
Earnings Date Nov 8, 2024

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign struc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 29
Stock Exchange Toronto Stock Exchange
Ticker Symbol EPRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.